| 1550 |
National Cancer Institute |
Html |
en |
Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma. |
| red blood cells | 0.477588 |
| Lymphocyte-depleted Hodgkin lymphoma | 0.50617 |
| cancer treatment | 0.499962 |
| malignant tumor cells | 0.49761 |
| body | 0.493073 |
| PDQ cancer information | 0.490723 |
| Non-Hodgkin Lymphoma Treatment | 0.479804 |
| clinical trial search | 0.486742 |
| white blood cells | 0.496539 |
| Low-risk childhood Hodgkin | 0.469047 |
| Intermediate-risk childhood Hodgkin | 0.468746 |
| clinical trials | 0.681512 |
| recurrent hodgkin lymphoma | 0.512969 |
| cancer information summary | 0.473675 |
| clinical trial | 0.539017 |
| -predominant childhood Hodgkin | 0.466011 |
| blood cells | 0.515545 |
| weight loss | 0.482905 |
| refractory Hodgkin lymphoma | 0.492835 |
| lymph nodes | 0.518888 |
| sclerosis Hodgkin lymphoma | 0.505736 |
| radiation therapy | 0.568298 |
| childhood hodgkin lymphoma | 0.931364 |
| lymph node groups | 0.523619 |
| Lymphocyte-rich classical Hodgkin | 0.468116 |
|
| treatment | 0.589509 |
| night sweats | 0.484683 |
| High-risk childhood Hodgkin | 0.468559 |
| Hodgkin Lymphoma Treatment | 0.532549 |
| classical childhood Hodgkin | 0.485325 |
| low-risk Hodgkin lymphoma | 0.490968 |
| recurrent childhood Hodgkin | 0.483388 |
| cancer cells | 0.532494 |
| cellularity Hodgkin lymphoma | 0.506213 |
| Untreated childhood Hodgkin | 0.4689 |
| lymphocyte-predominant Hodgkin lymphoma | 0.506119 |
| treatment clinical trials | 0.466252 |
| National Cancer Institute | 0.485234 |
| lymph vessels | 0.466622 |
| new treatment | 0.477189 |
| bone marrow | 0.510269 |
| PDQ summary | 0.464519 |
| hodgkin lymphoma | 0.996696 |
| cancer clinical trials | 0.496286 |
| classical hodgkin lymphoma | 0.530289 |
| swollen lymph nodes | 0.502296 |
| lymphocyte-predominant childhood Hodgkin | 0.463387 |
| cancer | 0.737848 |
| information | 0.498307 |
|
CLICK HERE |
| 1613 |
National Cancer Institute |
Html |
en |
Milk Thistle (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer. |
| skin cancer | 0.626682 |
| silibinin | 0.690395 |
| Silybum marianum | 0.601821 |
| cell lines | 0.721716 |
| silybin | 0.669258 |
| cell growth | 0.69811 |
| prostate cancer cell | 0.66523 |
| silymarin treatment | 0.604627 |
| cancer cell growth | 0.625622 |
| body weight | 0.623855 |
| human prostate carcinoma | 0.68146 |
| cancer epithelial cells | 0.601164 |
| glioma cell lines | 0.609591 |
| isolated compound silymarin | 0.617496 |
| Cancer Res | 0.643092 |
| human liver cells | 0.615903 |
| prostate cancer cells | 0.651126 |
| prostate carcinoma cells | 0.621206 |
| liver | 0.635065 |
| patients | 0.607034 |
| effects | 0.642741 |
| mild laxative effect | 0.607369 |
| Clin Cancer Res | 0.601341 |
| effect | 0.675634 |
| flavonoid antioxidant silymarin | 0.723144 |
|
| cancer chemopreventive effects | 0.614128 |
| cancer cells MDA-MB | 0.601463 |
| et al. | 0.630532 |
| Biophys Res Commun | 0.659514 |
| human colorectal cancer | 0.630373 |
| flavonoid hepatoprotector silymarin | 0.616137 |
| cancer cells | 0.687834 |
| cancer cell lines | 0.67658 |
| Biochem Biophys Res | 0.658799 |
| PUBMED Abstract | 0.644662 |
| ovarian cancer cells | 0.604482 |
| Silymarin effects | 0.60576 |
| studies | 0.607771 |
| liver function tests | 0.604338 |
| breast cancer cell | 0.607955 |
| cancer cell lines. | 0.620697 |
| silymarin | 0.927821 |
| silymarin stimulates synthesis | 0.619814 |
| cell cycle | 0.608497 |
| Abstract | 0.706375 |
| prostate cancer | 0.673752 |
| cancer | 0.736552 |
| dietary silymarin | 0.618331 |
| milk thistle | 0.829966 |
|
CLICK HERE |
| 1890 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama). |
| estadio lllC | 0.524041 |
| siguientes procedimientos | 0.510716 |
| siguientes aspectos | 0.534365 |
| causa efectos | 0.516747 |
| estadio lllB | 0.524512 |
| estadio lllA | 0.524967 |
| rayos x | 0.508877 |
| causó hinchazón | 0.508591 |
| cuáles lesiones | 0.508991 |
| Breast Cancer Risk | 0.519727 |
| epidérmico humano tipo | 0.51911 |
| carcinoma lobulillar | 0.618686 |
| crecimiento llamada her2 | 0.513006 |
| cuerpo llamada ecograma | 0.530459 |
| pared torácica.ampliar mastectomÃa | 0.517551 |
| siguientes estadios | 0.514163 |
| proteÃna tipo factor | 0.510936 |
| células madre | 0.671831 |
| estadio iv | 0.594708 |
| ganglio linfático centinela | 0.990128 |
| Oncotype DX | 0.510563 |
| estadio ib | 0.547143 |
| prueba ayuda | 0.524997 |
| enlace drugs approved | 0.56421 |
| estadio ia | 0.546556 |
|
| mama.ampliar cirugÃa | 0.509968 |
| CLIS.Ampliar Carcinoma lobulillar | 0.520349 |
| efectos tardÃos | 0.515275 |
| proteÃna her2 | 0.510017 |
| CaracterÃsticas genéticas | 0.510197 |
| bulbos minúsculos | 0.511767 |
| Breast Cancer Treatment | 0.519669 |
| cuántos genes | 0.511329 |
| incisión separada.ampliar mastectomÃa | 0.517497 |
| estadio iiia | 0.543785 |
| antecedentes familiares | 0.532316 |
| cabo pruebas | 0.51404 |
| estadio iiic | 0.596075 |
| estadio llB | 0.525023 |
| estadio llA | 0.525437 |
| Gynecologic Cancers | 0.511174 |
| mama.ampliar mamografÃa | 0.511179 |
| proteÃna llamada mTOR | 0.510238 |
| Breast Cancer | 0.623769 |
| sección cáncer | 0.744984 |
| pequeñas llamadas lobulillos | 0.518854 |
| genes brca1 | 0.512161 |
| siguientes pruebas | 0.535819 |
| siguientes sumarios | 0.517679 |
|
CLICK HERE |
| 3447 |
National Cancer Institute |
Html |
es |
Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el cese de fumar. |
| inglés quitguide | 0.387847 |
| voluntarios sanos | 0.399525 |
| mejores formas | 0.386123 |
| siguientes afecciones | 0.472657 |
| tabaco causa | 0.867887 |
| siguientes productos | 0.425294 |
| menor cantidad | 0.421673 |
| largo plazo | 0.418123 |
| cuánto tiempo | 0.427364 |
| Salud Pública | 0.42102 |
| PDQ Consumo | 0.504465 |
| Lung Health Study | 0.500728 |
| inglés llamadas tratamiento | 0.496113 |
| National Cancer Institute | 0.439195 |
| Más personas | 0.44409 |
|
| siguientes riesgos | 0.405102 |
| Instituto Nacional | 0.538387 |
| Leucemia mieloide aguda | 0.525345 |
| importantes beneficios | 0.399221 |
| Physician Data Query | 0.786005 |
| Estados Unidos | 0.979435 |
| prevención revisa | 0.406999 |
| Internet www.espanol.smokefree.gov | 0.394612 |
| siguientes medidas | 0.45081 |
| siguientes recursos | 0.434379 |
| principal causa | 0.695094 |
| Public Health Service | 0.49625 |
| tabaco encendido | 0.560371 |
| Quit Smoking Today | 0.481661 |
| enfermedades respiratorias | 0.409989 |
|
CLICK HERE |
| 3516 |
National Cancer Institute |
Html |
en |
Phases of Clinical Trials |
Information about the phases of cancer clinical trials. If a new treatment is successful in one phase, it will proceed to further testing in the next phase. |
| phase | 0.792058 |
| new treatment | 0.947877 |
| trial phases | 0.360482 |
| current standard therapy | 0.316008 |
| new cancer treatments | 0.34108 |
|
| phase clinical trials | 0.478655 |
| early phases | 0.271363 |
| phases | 0.375183 |
| drug treatment trials | 0.287914 |
|
CLICK HERE |
| 15607 |
National Cancer Institute |
Html |
en |
RAS Spokes/Funding |
null |
| Target KRAS-driven Cancer | 0.470287 |
| Memorial Sloan Kettering | 0.519803 |
| postdoctoral fellowship awardees | 0.536142 |
| mutant KRAS genes | 0.739519 |
| Kettering Cancer Center | 0.57102 |
| cell lung cancers | 0.454 |
| KRAS-Dependent Synthetic Lethality | 0.494023 |
| synthetic lethalities | 0.645951 |
| Oncogenic KRAS Synthetic | 0.736037 |
| pancreatic cancer research | 0.594341 |
| colorectal cancer | 0.483021 |
| Stanford University School | 0.433776 |
| cancer patient-derived organoids | 0.505737 |
| Sloan Kettering Cancer | 0.56303 |
| patient-derived xenografts | 0.489445 |
| mutant KRAS | 0.946717 |
| pancreatic cancer community | 0.516641 |
| human lung cancers | 0.451785 |
| small molecule screens | 0.437567 |
| Pancreatic Cancer Action | 0.760787 |
| mouse models | 0.516476 |
| Cancer Research Center | 0.504949 |
| RAS team | 0.447514 |
| KRAS co-dependencies | 0.626256 |
|
| KRAS research | 0.731632 |
| cancer research | 0.612188 |
| pancreatic cancer | 0.855519 |
| RAS Initiative workshop | 0.507302 |
| KRAS Synthetic Lethal | 0.86327 |
| KRAS Mutant Lung | 0.726016 |
| common mutant KRAS | 0.721287 |
| activity-based proteomic screens | 0.446336 |
| Finding KRAS Vulnerabilities | 0.720626 |
| PanCan KRAS Postdoctoral | 0.721221 |
| Frederick National Laboratory | 0.644503 |
| Synthetic Lethal Interactors | 0.486265 |
| Synthetic Lethality Screens | 0.508669 |
| Mutant KRas-Dependent Cancers | 0.505292 |
| KRAS effector pathways | 0.684876 |
| Cancer Action Network | 0.707609 |
| Deaconess Medical Center | 0.441844 |
| KRAS effectors | 0.653247 |
| Synthetic Lethal Relationships | 0.482397 |
| RAS Initiative | 0.631295 |
| colorectal cancer cells | 0.482928 |
| function high-throughput screens | 0.439806 |
| different KRAS mutations | 0.711715 |
| Synthetic Lethality | 0.582272 |
|
CLICK HERE |
| 16636 |
National Cancer Institute |
Html |
en |
Medicinal Mushrooms (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of medicinal mushrooms as a treatment for people with cancer. |
| cancer treatment | 0.568036 |
| chemotherapy | 0.524006 |
| PDQ cancer information | 0.669265 |
| lung cancer | 0.653736 |
| turkey tail | 0.777237 |
| reishi | 0.530583 |
| clinical trials | 0.606551 |
| U.S. Food | 0.502811 |
| cancer information summary | 0.619393 |
| alternative cancer therapies | 0.507487 |
| clinical trial | 0.529456 |
| colorectal cancer | 0.606284 |
| patients | 0.718186 |
| cancer patients | 0.586364 |
| gastric cancer patients | 0.525923 |
| PSK | 0.651884 |
| adjuvant therapy | 0.587394 |
| randomized clinical trial | 0.511048 |
| standard cancer treatments | 0.505852 |
| NCI PDQ cancer | 0.523643 |
| reishi mushrooms | 0.522541 |
| complementary therapies | 0.52479 |
| radiation therapy | 0.555862 |
| Therapies Editorial Board | 0.505693 |
|
| medicinal mushrooms | 0.712501 |
| Complementary Therapies Editorial | 0.519822 |
| Drug Administration | 0.559401 |
| Cancer Information Specialist | 0.499441 |
| Cancer Information Service | 0.564175 |
| advanced lung cancer | 0.497196 |
| standard cancer treatment | 0.517619 |
| dietary supplements | 0.500703 |
| National Cancer Institute | 0.663466 |
| long time | 0.498745 |
| alternative medicine | 0.537174 |
| lung cancer patients | 0.520738 |
| gastric cancer | 0.558768 |
| turkey tail mushrooms | 0.548558 |
| traditional Chinese medicine | 0.562629 |
| breast cancer | 0.533457 |
| health | 0.507834 |
| animal studies | 0.621773 |
| natural killer cells | 0.503348 |
| active compound PSK | 0.527105 |
| alternative therapies | 0.524113 |
| cancer information summaries | 0.503919 |
| comprehensive cancer information | 0.503793 |
| cancer | 0.900533 |
|
CLICK HERE |
| 16684 |
National Cancer Institute |
Html |
en |
Immunotherapy |
Immunotherapy is treatment that helps your immune system fight cancer. Get information about the different types of immunotherapy and what you can expect during treatment. |
| different ways | 0.281527 |
| fatal allergic reactions | 0.264895 |
| Certain immunotherapies | 0.259316 |
| treatment vaccines | 0.275288 |
| cancer cells | 0.951751 |
| new healthy cells | 0.412417 |
| type | 0.312586 |
| adult cancer treatment | 0.355067 |
| immune system fight | 0.336993 |
| cancer treatment summaries | 0.489214 |
| body’s cells | 0.328519 |
| white blood cells | 0.50706 |
| immune response | 0.442108 |
|
| bladder cancer | 0.215882 |
| immunotherapy | 0.916869 |
| car t-cell therapy | 0.510597 |
| white blood cell | 0.291068 |
| biological therapy | 0.305661 |
| immune cells | 0.541167 |
| normal immune responses | 0.430369 |
| immunotherapies | 0.36897 |
| different types | 0.290719 |
| early skin cancer | 0.309312 |
| body fight infections | 0.317237 |
| childhood cancer treatment | 0.34975 |
| adoptive cell transfer | 0.589329 |
|
CLICK HERE |
| 16858 |
National Cancer Institute |
Html |
en |
Monitoring Research Grant Awards |
NCI grants management staff regularly monitor individual grants within each budget period and within the overall project period. |
| program director | 0.901745 |
| overall project period | 0.737705 |
| Comptroller General | 0.577687 |
| documents | 0.447442 |
| Grants management officer | 0.721935 |
| grants management specialist | 0.810551 |
| federal regulation | 0.560169 |
| HHS awarding agency | 0.720873 |
| NCI staff work | 0.714177 |
| assessment | 0.459846 |
| progress reports | 0.591992 |
| budget period | 0.591377 |
| review | 0.454674 |
| weaknesses | 0.464168 |
| grants management | 0.917818 |
| telephone numbers | 0.566417 |
| financial reports | 0.599567 |
| required retention period | 0.705874 |
| reasonable access | 0.563534 |
| grant awards | 0.568767 |
| responsible GMS | 0.614785 |
| award process | 0.554431 |
| approved project | 0.590335 |
| recipients | 0.469243 |
| recipient cash expenditure | 0.886855 |
|
| NCI grants management | 0.812999 |
| problems | 0.44631 |
| recipient institution | 0.874163 |
| United States | 0.564008 |
| records | 0.447146 |
| audit reports | 0.592365 |
| site visits | 0.586368 |
| scientific progress | 0.547344 |
| Inspector General | 0.563508 |
| mutually agreeable course | 0.708418 |
| recipient’s inability | 0.723309 |
| internal controls | 0.570063 |
| Expenditure patterns | 0.599349 |
| financial systems | 0.589323 |
| pass-through entity | 0.56408 |
| monitors individual grants | 0.762977 |
| applicant organization | 0.594032 |
| unrestricted access | 0.5713 |
| principal investigator | 0.553317 |
| financial management | 0.584417 |
| specific guidelines | 0.567884 |
| management systems | 0.560429 |
| economic policy | 0.555241 |
| grant expenditures | 0.689873 |
|
CLICK HERE |
| 17291 |
National Cancer Institute |
Html |
es |
Uso de recursos fidedignos |
Información para ayudarle al público a evaluar las fuentes y la credibilidad de la información de salud impresa o disponible en Internet. |
| información personal | 0.935578 |
| siguientes preguntas | 0.82336 |
| conocimientos del cáncer que | 0.776836 |
| Comisión Federal | 0.674467 |
|
| Clinical Oncology | 0.664087 |
| American Society | 0.659703 |
| numerosos sitios | 0.822963 |
| acepte recomendaciones | 0.778707 |
|
CLICK HERE |